On June 5, 2017 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, reported that Mustang Bio, Inc. ("Mustang"), a subsidiary of Fortress, has entered into exclusive, worldwide licensing agreements with City of Hope ("COH") for the use of three novel CAR T therapies in the development of cancer treatments (Press release, Fortress Biotech, JUN 5, 2017, View Source [SID1234519371]). Schedule your 30 min Free 1stOncology Demo! The CAR T therapies covered under the agreements include: human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme; CS1‐specific CAR T technology (CS1 Technology) to be directed against multiple myeloma; and prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the treatment of prostate cancer. All three technologies were developed in the laboratory of Stephen J. Forman, M.D., director of COH’s T cell Immunotherapy Research Laboratory.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Manuel Litchman, President and Chief Executive Officer of Mustang, said, "We believe the in‐licensing of this COH technology will enable us to expand our CAR T portfolio through the application of novel product candidates and new indications. We look forward to our continued partnership with Dr. Forman and his team at COH, as we work together to advance cutting‐edge treatment options for cancer patients."
This announcement builds upon established exclusive patent license agreements that Mustang has entered into with COH related to Mustang’s lead CAR T therapies, MB‐101 (IL13Rα2‐specific CAR) and MB‐102 (CD123 CAR), spacer technology to be used in the development of CAR T treatments, and intraventricular and intracerebroventricular methods of delivering T cells that express CARs.